Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BYSI 
BeyondSpring Inc (BYSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BYSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 9.28% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.91M USD | Price to earnings Ratio - | 1Y Target Price 1.25 |
Price to earnings Ratio - | 1Y Target Price 1.25 | ||
Volume (30-day avg) 12630 | Beta 0.3 | 52 Weeks Range 1.37 - 3.62 | Updated Date 03/30/2025 |
52 Weeks Range 1.37 - 3.62 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -742.2% |
Management Effectiveness
Return on Assets (TTM) -39.64% | Return on Equity (TTM) -310.48% |
Valuation
Trailing PE - | Forward PE 10.54 | Enterprise Value 55520919 | Price to Sales(TTM) 31.22 |
Enterprise Value 55520919 | Price to Sales(TTM) 31.22 | ||
Enterprise Value to Revenue 26.53 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 40300400 | Shares Floating 25279604 |
Shares Outstanding 40300400 | Shares Floating 25279604 | ||
Percent Insiders 25.54 | Percent Institutions 13.79 |
Analyst Ratings
Rating 5 | Target Price 1.13 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BeyondSpring Inc
Company Overview
History and Background
BeyondSpring Inc. was founded in 2010. It is a global biopharmaceutical company focused on developing innovative cancer therapies.
Core Business Areas
- OncoDifferentiated Assets: Development of drugs that target cancer cells while sparing healthy cells. Plinabulin is their lead asset.
- Immuno-Oncology Assets: Development of drugs that leverage the body's immune system to fight cancer.
Leadership and Structure
Dr. Lan Huang is the co-founder, CEO and Chairwoman. The company operates with a typical biopharmaceutical structure, including research, clinical development, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- Plinabulin: A selective guanine nucleotide exchange factor (GEF) inhibitor that is in development for the treatment of chemotherapy-induced neutropenia (CIN) and non-small cell lung cancer (NSCLC). Competitors for CIN include Neulasta (Amgen), Neupogen (Amgen), and Granix (Teva).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated. It's characterized by high research and development costs, long development timelines, and significant regulatory hurdles.
Positioning
BeyondSpring is a clinical-stage biopharmaceutical company aiming to address unmet medical needs in cancer therapy, specifically focusing on CIN and NSCLC. They are positioned as an innovator in the onco-differentiated therapy space.
Total Addressable Market (TAM)
The TAM for CIN is estimated to be significant, potentially reaching billions of dollars globally. The NSCLC market is also very large. BeyondSpring's positioning in the onco-differentiated and immuno-oncology spaces gives them access to segments of this large TAM.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Experienced management team
- Lead asset with potential to address unmet medical needs
- Partnerships with established pharmaceutical companies
Weaknesses
- Limited commercial infrastructure
- Dependence on clinical trial success
- Significant financing needs
- Plinabulin US FDA rejection of NSCLC
Opportunities
- Expansion into new indications
- Strategic collaborations and licensing agreements
- Market approval and commercialization of Plinabulin
- Further development of immuno-oncology assets
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
- Market access and reimbursement challenges
Competitors and Market Share
Key Competitors
- AMGN
- TEVA
- GILD
Competitive Landscape
BeyondSpring is at a disadvantage in terms of market share, funding, and brand recognition due to being a clinical-stage biopharmaceutical company compared to large players in the industry. However, it has the potential advantage of novel mechanisms of action of their drugs, if proven effective.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on previous financial data and clinical trial results, which are constantly fluctuating.
Future Projections: Future projections require analyst estimates and depend on drug approval and market acceptance.
Recent Initiatives: Focus on Plinabulin's regulatory approval in key markets (China) and potential new clinical trials.
Summary
BeyondSpring is a clinical-stage biopharmaceutical company with a focus on cancer therapies. The company faces significant challenges, including regulatory hurdles, competition from established pharmaceutical companies, and dependence on clinical trial success. Its strengths lie in its innovative technology platform and experienced management team. Successful commercialization of Plinabulin in key markets, particularly China, will be critical for its future growth and to mitigate its existing weakness.
Similar Companies
- AMGN
- MRTX
- GILD
- TEVA
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BeyondSpring Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2017-03-09 | Co-Founder, Chairman & CEO Dr. Lan Huang Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://beyondspringpharma.com |
Full time employees - | Website https://beyondspringpharma.com | ||
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.